Allist Pharmaceuticals, Inc.

This study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…

This early-stage study tests a new tablet, AST2303, in 120 people with advanced non-small cell lung cancer that has spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or slow the disease. Participants will take…

This trial tests whether taking firmonertinib after surgery can help prevent non-small cell lung cancer from coming back in people with certain uncommon EGFR mutations. Participants who had their tumor completely removed will receive either firmonertinib or a placebo daily. The s…

This early-phase trial is testing whether combining two experimental drugs, JAB-21822 and JAB-3312, can safely shrink or control advanced solid tumors that carry a specific KRAS G12C mutation. The study includes people with cancers like non-small cell lung, colorectal, or pancrea…

This trial is testing an oral drug called JAB-21822 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation along with an STK11 mutation. The study aims to see if the drug is safe, tolerable, and effective in shrinking tumors. Partic…

This study tests whether a new drug called furmonertinib, given with chemotherapy, works better than the current standard drug osimertinib for people with a specific type of lung cancer (EGFR-mutant non-squamous NSCLC) that has spread to the brain. About 380 adults whose cancer h…

This trial is testing whether the drug furmonertinib can help prevent non-small cell lung cancer from coming back after surgery. The study enrolls adults with stage II-IIIA lung cancer that has specific EGFR mutations and who have had the tumor completely removed, with or without…

This phase 3 trial is investigating whether a combination of two oral drugs, JAB-21822 and JAB-3312, can work better than the current standard treatment (immunotherapy plus chemotherapy) as a first-line therapy for people with advanced non-squamous non-small cell lung cancer that…

This phase 2 trial is testing a daily pill called JAB-21822 (Glecirasib) in 88 people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. Participants must have already tried standard treatments without success. The main goal is to see i…